15 matches for your search in the start-up spotlight
rss
Michael Bauer from Novo Holdings and Lucille Conroy from Abingworth will join Myricx Bio Board of Directors
16-Jul-2024
Myricx Bio, a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), announced the closing of its series A financing raising £90m ($114m). The round was co-led by new leading life science investors Novo Holdings ...
In successful funding rounds, three LMU spin-offs have brought in investments worth millions.
25-Jun-2024
Tubulis, Smart Reporting, and Eisbach Bio have successfully attracted new investor funding. The new capital will enable the companies, for example, to expand their research and development activities. Tubulis and Eisbach develop new therapeutic approaches and active agents for cancer treatment, ...
"This substantial financing from a syndicate of global specialist biotech investors recognizes Tubulis’ unique position in the ADC space"
18-Mar-2024
Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led byEQT Life Sciences and Nextech Invest Ltd, on behalf of one or more funds managed by it, with participation from new US-based funds, Frazier Life ...
"DISCO is uniquely positioned to transform cancer care"
18-Jan-2024
DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking thesurfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth. The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing ...
Focus on accelerated development of differentiated antibody-drug conjugates therapeutics for solid tumors
04-Apr-2023
BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. (DualityBio), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate (“ADC”) therapeutics to treat patients with cancer and autoimmune diseases, announced that the companies have ...
"Araris continues to make waves in the industry with its pioneering linker technology, enabling fast and precise production of ADCs"
10-Oct-2022
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date. The round was co-led by 4BIO Capital and Pureos Bioventures, with participation ...
Aims to advance its lead ADC compound targeting a novel cancer antigen
04-Oct-2022
Pheon Therapeutics (Pheon), a Antibody-Drug Conjugate(ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, launched following the closing of a $68 million Series A financing in March 2022. The investment will enable Pheon to advance its lead ADC program to ...
Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours
21-Jun-2022
Spirea Limited, a Cambridge company created to advance a new generation of antibody drug conjugate (ADC) therapeutics, has announced that it has secured funding of £2.4 million ($3M) with investments from high-profile UK and US investors. Spirea will use the funds to initiate its pipeline of ...
Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
05-May-2022
Tubulis announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), ...
Lead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicity
08-Dec-2021
Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, announces that it has closed an €87 million series A financing round. The round was led by Pontifax Venture Capital and includes RA Capital ...
